Generalized Anxiety Disorder (GAD)

1. Clinical Overview

Summary

Generalized Anxiety Disorder (GAD) is a chronic, prevalent mental health condition characterized by excessive, uncontrollable, and irrational worry ("apprehensive expectation") about everyday events (work, health, finances) occurring more days than not for at least 6 months. Unlike Panic Disorder (episodic terror) or Phobias (specific triggers), the anxiety in GAD is "free-floating" and pervasive.

The core pathology involves dysregulation of the amygdala-prefrontal cortex circuit, with deficits in GABAergic inhibition and Serotonin signaling. Patients live in a state of constant "Fight or Flight" arousal, leading to significant somatic burden (muscle tension, fatigue, insomnia) and functional impairment. It is highly comorbid with Major Depressive Disorder (up to 60%). [1,2]

GAD is associated with substantial disability and economic burden, with many cases remaining undiagnosed despite significant impact on health-related quality of life. [3] The disorder affects up to one in five people at some point in their lives, with less than half achieving full remission after 5 years. [4]

Management follows a stepped-care model (NICE CG113), progressing from active monitoring and psychoeducation to High-Intensity CBT and Pharmacotherapy (SSRIs such as Sertraline are first-line). Pregabalin is a robust second-line option for somatic symptoms. Benzodiazepines are reserved for crisis management only due to dependence risks. [5,6]

Key Facts

• Definition: Excessive worry > 6 Months, difficult to control, associated with 3+ somatic symptoms (Restlessness, Fatigue, Concentration, Irritability, Tension, Sleep).
• Prevalence: 5-6% lifetime prevalence. F:M ratio 2:1.
• Core Cognition: "What if...?" (Catastrophizing).
• Gold Standard Screen: GAD-7 (Score ≥10 = Probable GAD).
• First Line Drug: Sertraline 50mg or Escitalopram 10mg.
• Number Needed to Treat (NNT): Antidepressants in GAD: 5.15. [7]

Clinical Pearls

Clinical Pearl: The "Worry about Worry": A hallmark feature of GAD is "Meta-worry". Patients worry that their worrying will drive them crazy or make them physically ill. This cycle reinforces the anxiety.

Clinical Pearl: Somátic Presentation: Many GAD patients present to GPs with physical complaints: "Tension headaches"

• "IBS"
• "Fibromyalgia", or "Insomnia". Always screen for anxiety in patients with "medically unexplained symptoms".

Clinical Pearl: "Tired but Wired": Patients report being exhausted all day (fatigue) but unable to sleep at night (insomnia/racing thoughts). This specific type of insomnia is classic for GAD.

Clinical Pearl: Alcohol as Self-Medication: Up to 30% of GAD patients use alcohol to "numb" the anxiety (GABA agonist). Treating the anxiety often resolves the "alcohol problem". Always ask: "Do you drink to relax?"

Clinical Pearl: Attentional Bias to Threat: Individuals with GAD demonstrate consistent attentional bias toward threat-related stimuli, though findings vary across different measurement paradigms. [8] This bias contributes to the maintenance of chronic worry.

Why This Matters Clinically

Disability: GAD causes more "days out of role" than depression alone. Physical Health: Associated with increased risk of Cardiovascular Disease (chronic sympathetic overdrive). Suicide Risk: Significant risk factor, especially when comorbid with depression. Economic Burden: GAD imposes substantial healthcare costs and productivity losses, particularly among undiagnosed cases. [3]

---

2. Epidemiology

Prevalence & Incidence

• Lifetime Prevalence: ~5-6%. Up to 20% may experience GAD at some point in their lives. [4]
• One-Year Prevalence: ~3%.
• Demographics: More common in women (2:1). Prevalence peaks in middle age (45-54), but onset is often in adolescence or early adulthood.
• Course: Chronic and fluctuating. Remission rates without treatment are low. Less than half of people have full remission after 5 years. [4]
• Treatment Rates: Poor detection and treatment rates despite high prevalence and significant impact. [9]

Global Burden

GAD represents a significant public health challenge worldwide. During the COVID-19 pandemic, prevalence among healthcare workers increased substantially, highlighting the impact of chronic stressors on GAD incidence. [10]

Risk Factors

Pediatric and Adolescent Considerations

Onset often occurs in childhood or adolescence, with excessive worry and tension about everyday events that the child cannot control. Early identification and intervention are critical for preventing chronic course. [12]

Prognostic Indicators

Poor outcome predictors: [11]

• Severe initial symptoms
• Multiple comorbidities
• Childhood trauma history
• Female gender
• Lack of social support
• Chronic medical conditions

---

3. Pathophysiology

The "Fear Circuit" Dysregulation

Anxiety is a normal survival mechanism. GAD is a "false alarm" system stuck in the "ON" position.

Stepwise Pathophysiology: The Neurobiological Cascade

Step 1: The Threat Perception (Amygdala Overactivity)

• The Amygdala (Fear Center) perceives neutral stimuli as threatening.
• It is hyper-reactive and fails to habituate to stressors.
• fMRI studies consistently demonstrate amygdala hyperactivation in GAD patients during emotional processing tasks. [13]

Step 2: Failure of "Top-Down" Control (PFC Deficit)

• The Prefrontal Cortex (PFC - Logical Brain) normally inhibits the Amygdala ("It's just a bill, not a tiger").
• In GAD, the connection is weak. The PFC cannot dampen the Amygdala's firing.
• Neuroimaging reveals reduced prefrontal cortex activation and impaired functional connectivity between PFC and amygdala. [13]
• The dorsolateral prefrontal cortex (dlPFC) shows particularly reduced activity during cognitive control tasks. [13]

Step 3: Neurotransmitter Imbalance

• GABA Deficit: Gamma-Aminobutyric Acid is the main inhibitory neurotransmitter (The "Brakes"). GAD brains have low GABA activity.
• Serotonin Dysregulation: 5-HT regulates mood and anxiety. Receptors (5-HT1A) are down-regulated.
• Noradrenaline Surge: Locus Coeruleus pumps out Norepinephrine -> Physical arousal.
• These neurotransmitter systems form the basis for pharmacological interventions. [14]

Step 4: HPA Axis Activation (Chronic Stress)

• Hypothalamus -> Pituitary -> Adrenal -> Cortisol.
• Hippocampal Atrophy: Cortisol is neurotoxic to the Hippocampus (memory/context).
  • Result: Loss of "Contextual Fear Extinction". The brain can't distinguish a "safe" context from a "dangerous" one. The hippocampus normally provides the "context" ("That is a snake in a zoo, not in my bed"). When it shrinks, context is lost.
• BDNF Reduction: Brain-Derived Neurotrophic Factor levels drop, preventing neuroplasticity (healing). This explains why recovery is slow without treatment.

Step 4 b: The Bed Nucleus of the Stria Terminalis (BNST)

• While the Amygdala mediates fear (immediate threat), the BNST mediates anxiety (sustained, future threat).
• In GAD, the BNST is chronically hyperactive, maintaining a state of "sustained vigilance".
• This distinction helps explain the difference between panic (amygdala-mediated) and chronic worry (BNST-mediated). [13]

Step 5: The "Worry Loop" (Cognitive Maintenance)

• Worry becomes a coping mechanism ("If I worry, I can prevent the bad thing").
• This "safety behavior" prevents the patient from learning that the catastrophe wouldn't happen anyway (Failure of Extinction Learning).
• Meta-cognitive beliefs about worry (both positive: "worry helps me prepare" and negative: "worry is dangerous") maintain the disorder.

Step 6: Somatic Manifestation

• Chronic muscle tension leads to pain (Headaches, Back pain).
• Autonomic arousal leads to GI distress (IBS link).
• Cardiovascular effects include increased heart rate variability and elevated blood pressure. [1]

Neuropsychological Profile

Patients with GAD demonstrate specific cognitive patterns: [15]

• Impaired executive function
• Attentional bias to threat
• Difficulty with cognitive flexibility
• Enhanced threat detection but impaired threat dismissal
• Working memory deficits during high anxiety states

Neuroimaging Findings Summary

fMRI studies in GAD consistently show: [13]

1. Amygdala hyperactivation to emotional stimuli
2. Reduced prefrontal cortex activation
3. Impaired connectivity between regulatory (PFC) and emotional (amygdala) regions
4. Abnormal activation in anterior cingulate cortex
5. Altered activation in insula (interoceptive awareness center)

These findings support theoretical cognitive models emphasizing dysregulation in emotional processing and cognitive control networks.

---

4. Clinical Presentation

Core Diagnostic Criteria (DSM-5 Summary)

A. Excessive anxiety/worry (more days than not) for ≥ 6 months. B. Difficult to control the worry. C. Associated with 3 or more of:

1. Restlessness / Keyed up / On edge.
2. Fatigue (easily tired).
3. Concentration difficulty (Mind going blank).
4. Irritability.
5. Muscle Tension.
6. Sleep Disturbance. D. Functional Impairment.

The "Anxious Phenotype"

Patients often present with "Worry Themes":

• Health: "Is this headache a tumor?"
• Family: "Are my kids safe at school?"
• Finances: "Will I lose my job?"
• Performance: "Did I say the wrong thing?"

The worry is typically multifocal, shifting between different domains, and characterized by "What if?" thinking patterns.

Differential Diagnosis Comparison (Comprehensive)

Medical Mimics of Anxiety

Exclude these "Great Masqueraders":

• Endocrine: Hyperthyroidism, Pheochromocytoma, Carcinoid Syndrome, Hypoglycemia.
• Cardiac: SVT, AF, Mitral Valve Prolapse.
• Respiratory: Asthma, COPD, Pulmonary Embolism (Hypoxia causes anxiety).
• Neurological: Temporal Lobe Epilepsy (Aura), Vestibular dysfunction.
• Substance: Caffeine intoxication, Cocaine, Alcohol Withdrawal, Steroids.

Red Flags

[!CAUTION] Psychiatry Red Flags - Immediate Referral if:

• Suicidality: Active plans or intent.
• Psychosis: Hearing voices or paranoid delusions.
• Self-Neglect: Not eating/drinking due to anxiety.
• Substance Withdrawal: Risk of seizures (Benzos/Alcohol).

Emotion Recognition Patterns

Recent research indicates that GAD patients may demonstrate altered patterns of emotion recognition, potentially contributing to interpersonal difficulties and maintenance of anxiety symptoms. [16]

---

5. Clinical Examination

Structured History Taking Guide (The "GAD" Script)

When assessing a patient with "stress" or "worry", use this structured approach to tease out GAD from normal life stress.

1. The "Worry" Analysis

• "You mentioned being stressed. Can you tell me what specific things run through your mind?"
  • Look for: Multi-focal worry (money, health, kids, work, the cat, the car).
• "How much of your day is spent worrying? Is it an hour? Half the day? All day?"
  • Look for: "More days than not" and duration > 6 months.
• "Do you feel you can switch the worry off? If you want to relax, can you?"
  • Look for: Uncontrollability (Criterion B).

2. The Somatic Screen (The "Physical" Anxiety)

• "When the worry is bad, what does your body feel like?"
• "Do you feel restless, like you can't sit still?" (Restlessness).
• "Are your muscles tight? Shoulders? Jaw?" (Muscle Tension).
• "Are you tired all the time despite sleeping?" (Fatigue).
• "Do you find yourself snapping at people?" (Irritability).

3. The Risk Assessment

• "Does the worry ever get so bad you feel life isn't worth living?"
• "Do you use alcohol or weed to turn the noise down?"

4. The "Safety Behaviors" Check

• "Do you check your phone constantly to see if your kids are okay?"
• "Do you avoid watching the news?"
• "Do you ask your partner 'Is everything okay?' multiple times a day?"

Mental State Examination (MSE) Highlights

• Appearance: Tense posture, furrowed brow, restless hands (wringing), poor eye contact due to anxiety.
• Behavior: Fidgeting, tremor, startle response.
• Speech: Rapid, pressured, but usually interruptible.
• Mood: "Anxious"

• "Worried"
• "Tense".

• Affect: Anxious, reactive.
• Thought Content: Preoccupations with future disasters. No delusions.
• Insight: Usually preserved ("I know it's silly to worry, but I can't stop").

Physical Exam (Excluding Medical Causes)

• Thyroid: Palpate for Goitre.
• Pulse: Tachycardia (Anxiety or Thyrotoxicosis or Pheo).
• Neuro: Fine tremor (Hyperthyroid/Anxiety) vs Coarse tremor.

---

6. Investigations

Screening Tools: GAD-2 vs GAD-7

The GAD-2 (Rapid Screen) Used in primary care to rule-out anxiety.

• "Over the last 2 weeks, how often have you been bothered by:"
  1. Feeling nervous, anxious or on edge?
  2. Not being able to stop or control worrying?
• Score ≥ 3: Positive Screen (Sensitivity 86%). Proceed to GAD-7. [17]

The GAD-7 (Diagnostic Standard) The Gold Standard for identifying probable cases and monitoring severity. [17]

GAD-7 Table Interpretations

(Questions cover: Nervousness, Unable to stop worrying, Worrying about different things, Trouble relaxing, Restless, Irritable, Afraid something awful might happen).

The GAD-7 has excellent psychometric properties with high sensitivity and specificity for detecting GAD in primary care and specialist settings. [17]

Medical "Rule-Out" Panel

Before diagnosing a psychiatric disorder, exclude organic causes:

1. Thyroid Function Tests (TFTs): TSH/T4. (Hyperthyroidism mimics GAD).
2. FBC: Anemia (can cause tachycardia/fatigue).
3. U&E/Calcium: Electrolyte disturbances.
4. Glucose: Hypoglycemia episodes.
5. ECG: If palpitations present (Arrhythmia).
6. Urine Toxicology: Cannabis/Cocaine/Amphetamines (huge anxiety drivers).

Functional Assessment

Evaluate:

• Work/academic functioning
• Social relationships
• Activities of daily living
• Quality of life measures
• Economic impact (days off work, healthcare utilization)

---

7. Management

Management Algorithm

AI-Generated Management Algorithm Image Required:

Image

Algorithm Content (NICE CG113): [5]

1. Step 1: Identification & Education. "Active Monitoring".
2. Step 2 (Mild/GAD-7 less than 10): Low-Intensity CBT. (Self-help books, Computerized CBT, Group psychoeducation).
3. Step 3 (Moderate/Severe/Failed Step 2): High-Intensity CBT OR Pharmacotherapy (SSRI).
4. Step 4 (Complex/Refractory): Specialist referral. Multi-drug combinations.

1. Psychological Therapies (CBT Detailed)

Cognitive Behavioral Therapy (CBT) is the Gold Standard.

Recent network meta-analysis confirms CBT demonstrates both acute and long-term effectiveness, supporting its role as first-line therapy for GAD. [18] Effect sizes for CBT in GAD are large (d=0.8), superior to relaxation training alone. [19]

Core CBT Modules for GAD

Digital Interventions

Internet-delivered CBT represents an accessible, effective treatment option for GAD, potentially addressing barriers to traditional face-to-face therapy. Meta-analyses show significant efficacy for internet-based interventions. [9]

2. Pharmacotherapy (First Line: SSRIs)

Antidepressant Pharmacokinetics & Dosing Profile

Mechanism: Increase synaptic serotonin. Downregulate 5-HT receptors over time. Pearl: Start LOW (e.g., Sertraline 25-50mg). Anxiety patients are super-sensitive to the initial "jitteriness" side effect. Time to effect: 4-6 weeks (Slower than for depression). Duration: Continue for at least 12 months. Efficacy: NNT for antidepressants in GAD is 5.15. [7]

Network meta-analyses confirm SSRIs and SNRIs offer the best balance of efficacy and acceptability compared to other pharmacological classes. [21]

7b. Managing Common Side Effects (Adherence Guide)

3. Pharmacotherapy (Second Line)

Pregabalin

• Class: Calcium Channel Modulator (reduces Glutamate/Noradrenaline release).
• Indication: If SSRI/SNRI ineffective or not tolerated.
• Pros: Works FAST (within 1 week, by Day 4-7). [22] Good for somatic anxiety (tension).
• Cons: Sedation, Weight gain, Abuse potential (Class C drug).
• Evidence: Meta-analysis confirms rapid onset and efficacy comparable to benzodiazepines but with superior safety profile. [6,22]

SNRIs (Venlafaxine / Duloxetine)

• Mechanism: Serotonin + Norepinephrine reuptake inhibition.
• Evidence: Established as effective through multiple RCTs. [20]
• Cons: Discontinuation syndrome is severe ("Brain zaps").

4. What about Benzodiazepines?

• Diazepam, Lorazepam.
• NICE Says: Do NOT use for long-term treatment. [5]
• Role: Short-term crisis only (e.g., 2 weeks max) while waiting for SSRI to work.
• Risk: Tolerance develops in 2 weeks. Dependence.

5. Benzodiazepine Withdrawal Protocol

If a patient has been on long-term benzodiazepines (> 4 weeks), do NOT stop abruptly (Risk of Seizures).

The Slow Taper (Ashton Protocol Principle)

1. Switch: Convert short-acting (Lorazepam/Alprazolam) to matching Diazepam equivalent (Longer half-life = smoother levels).
2. Reduce: Reduce dose by 1/8th every fortnight.
3. Pause: If withdrawal symptoms occur (Rebound anxiety, tremor, insomnia), hold dose until stable.
4. Stop: Final 1mg can be the hardest.

6. Special Populations: Pregnancy & Lactation

7. Emerging Therapies

Repetitive Transcranial Magnetic Stimulation (rTMS) Systematic review and meta-analysis suggest potential efficacy for rTMS in GAD, offering a non-pharmacologic, non-psychotherapeutic alternative for treatment-resistant cases. [23]

8. WHO Global Recommendations

The World Health Organization (2024) has issued updated recommendations for management of GAD in general health care settings, emphasizing accessibility and evidence-based interventions. [24]

Patient Self-Care Techniques

---

8. Complications

1. Comorbidities

• Major Depression (60% overlap). [1,2]
• Substance Abuse (Alcohol to self-medicate).
• Other Anxiety disorders (Social, Panic).
• Most GAD patients have other health problems and comorbidities significantly worsen prognosis. [4]

2. Physical Health

• IBS (Irritable Bowel Syndrome).
• Fibromyalgia / Chronic Pain syndromes.
• Hypertension.
• Cardiovascular disease risk (chronic sympathetic activation).

3. Social

• Relationship breakdown (partner burnout from reassurance seeking).
• Occupational failure (avoidance/procrastination).
• Economic burden from lost productivity. [3]

4. Healthcare Utilization

• Increased emergency department visits
• Higher primary care consultation rates
• Greater use of medical investigations for somatic symptoms

---

9. Prognosis & Outcomes

• GAD is often chronic. "Waxing and Waning" course.
• Treatment efficacy: ~50-60% of patients respond to SSRI/CBT. [7,19]
• Long-term outcomes: Less than half achieve full remission after 5 years. [4]
• Predictors of poor outcome: Severe initial symptoms, comorbidity, childhood trauma, female gender. [11]
• Response to treatment: Internet-delivered and traditional CBT show sustained benefits at follow-up. [9,18]

Special Population Outcomes

Older Adults (≥55 years) Controlled interventions show efficacy in older adults, though treatment approaches may need modification for this population. [25]

Treatment-Resistant GAD Approximately 40-50% of patients do not achieve adequate response to first-line treatment, requiring stepped interventions including combination therapy, augmentation strategies, or novel treatments.

---

10. Evidence & Guidelines (Comprehensive)

Key Guidelines

1. NICE CG113 (2019) — Generalised anxiety disorder and panic disorder in adults: management. [PMID: 21270081] [5]
2. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines (2023). [PMID: 36987114]
3. CANMAT Guidelines (2012) — Management of Comorbid Anxiety. [PMID: 22426806] [26]
4. BAP Guidelines (2014) — Pharmacological treatment of anxiety. [PMID: 24713617] [19]
5. Clinical Practice Guidelines for GAD (2017). [PMID: 28216786]
6. WHO Recommendations (2024). [PMID: 38214633] [24]

Landmark Trials & Meta-Analyses (Grade A Evidence)

The Davidson Study (1999) - Venlafaxine

• Study: Venlafaxine XR vs Buspirone vs Placebo in GAD.
• Finding: Venlafaxine was significantly superior to placebo. Buspirone was less consistent.
• Impact: Established SNRI/SSRIs as the mainstay over older anxiolytics like Buspirone. [PMID: 10197828] [20]

The Baldwin Trials (2011) - Pregabalin

• Study: Meta-analysis of multiple RCTs of Pregabalin in GAD.
• Finding: Rapid onset of action (by Day 4-7) compared to weeks for SSRIs. Efficacy comparable to Benzos but safer.
• Impact: Elevated Pregabalin to a core treatment option, especially for somatic symptoms. [PMID: 21211105] [6]

The Cuijpers Meta-Analysis (2014)

• Study: Efficacy of Psychological treatments.
• Finding: CBT has a large effect size (d=0.8) for GAD, superior to relaxation training alone.
• Impact: Validated CBT as the psychotherapy of choice. [PMID: 24713617] [19]

The Slee Network Meta-Analysis (2019)

• Study: Comparison of all pharmacological classes.
• Finding: SSRIs and SNRIs offer the best balance of efficacy and acceptability. Quetiapine was effective but poorly tolerated.
• Impact: Confirmed SSRIs as first-line. [PMID: 30712879] [21]

The Zhang Meta-Analysis (2023) - Psychotherapies

• Study: Network meta-analysis of randomized clinical trials examining psychotherapies for GAD.
• Finding: CBT demonstrated associations with both acute and long-term effectiveness.
• Impact: Reinforced CBT as first-line therapy with sustained benefits. [PMID: 37851421] [18]

Internet-Delivered Interventions (2020)

• Study: Updated systematic review and meta-analysis of internet-delivered treatment.
• Finding: Significant efficacy for improving accessibility while maintaining effectiveness.
• Impact: Validated digital interventions as viable treatment modality. [PMID: 33225589] [9]

Systematic Reviews of Note

Attentional Bias (2017) Systematic review of experimental literature on attention to threat in GAD, establishing current evidence for attentional bias among high trait worriers. [PMID: 28448826] [8]

fMRI Studies (2014) Comprehensive systematic review of functional neuroimaging in GAD, providing neurobiological support for cognitive models. [PMID: 25020268] [13]

Neuropsychological Findings (2019) Systematic review of controlled studies evaluating neuropsychological performance in GAD adults. [PMID: 31287149] [15]

Economic Burden (2009) Systematic review and quality assessment of economic evaluations and quality-of-life studies. [PMID: 19695395] [27]

---

11. Patient/Layperson Explanation

The "Smoke Alarm" Analogy

Imagine your brain has a smoke alarm (The Amygdala) designed to keep you safe.

• Normal: It only beeps when there is a fire (real danger).
• GAD: The smoke alarm is broken. It beeps when you burn toast, when you light a candle, or even when the air is clear.
• You live your life with a loud siren going off constantly. You know logically there is no fire (Insight), but the noise makes your heart race and muscles tense anyway.
• Treatment: Medication turns the volume of the siren down. Therapy teaches you to check specifically for fire before panicking at the beep.

What to Expect from Treatment

• Timeline: Medications take 4-6 weeks to work fully. CBT requires 12-16 sessions typically.
• Improvement: Most people notice 50-60% reduction in symptoms.
• Maintenance: Treatment usually continues for 12-18 months after improvement.
• Relapse: Possible, but skills learned in therapy provide lifelong tools.

---

11b. Detailed Clinical Case Studies

Case 1: "The Worried Well" (Early Intervention)

Patient Profile: Sarah, 28, School Teacher. Presentation: Presents requesting a "sick note" for stress. Reports she is "burning out". History: "I wake up at 4am thinking about lesson plans. Then I worry if I locked the door. Then I worry about my mom's health (mom is fine). By the time I get to school I'm exhausted." MSE: Eye contact good but intense. Rapid speech. Hands gripping her bag. Diagnosis: GAD (Metaworry, Fatigue, Sleep disturbance, > 6 months). GAD-7 Score: 12 (Moderate). Management:

1. Psychoeducation: Explain the "Smoke Alarm" analogy. Validated her symptoms as anxiety, not just "stress".
2. Low Intensity: Prescribed "Guided Self Help" (CBT book on prescription).
3. Worry Time: Instructed to set a "20 minute worry window" at 5pm. Outcome: 4 weeks later, sleeping better. Anxiety manageable. No meds needed.

Case 2: "The Somatic Mask" (Diagnostic Challenge)

Patient Profile: David, 52, Accountant. Presentation: 5th visit in 2 months. Complaints: "Dizzy spells"

• "Tension headaches"
• "Stomach churning". Convinced he has a brain tumor or bowel cancer. History: Medical workup (MRI Brain, Colonoscopy, Bloods) all normal. He is frustrated: "Why can't you find what's wrong?". The Pivot: Doctor asks "David, when you get these headaches, what are you doing?" -> "I'm looking at spreadsheets worrying if I made a mistake that will bankrupt the company." Diagnosis: Severe GAD with Somatization. GAD-7 Score: 18 (Severe). Management:

1. Framing: "David, your pain is real. It's caused by high-voltage tension in your nervous system, like a car revving in neutral."
2. Pharmacotherapy: Started Sertraline 50mg. Warned about initial jitteriness.
3. Review: At 6 weeks, headaches gone. "I feel lighter".

Case 3: "Treatment Resistant & Comorbid" (Complex)

Patient Profile: Aisha, 44, Unemployed. Presentation: Chronic anxiety for 20 years. "I've always been a worrier". Currently depressed (low mood, hopelessness). History: Failed Citalopram (didn't work), Fluoxetine (too jittery). Drinking 1/2 bottle of wine nightly to sleep. Diagnosis: GAD + Major Depression + Alcohol Misuse. Management:

1. Alcohol: Discussed reduction. Alcohol is a depressant and anxiogenic upon withdrawal.
2. Med Prescribing: Switched to Pregabalin (Lyrica) 75mg BD. Rationale: Works fast, helps sleep, covers somatic anxiety, different mechanism to SSRI.
3. Referral: Referred for High Intensity CBT (Individual therapy). Outcome: Mood lifted as anxiety reduced. Alcohol intake dropped naturally as sleep improved on Pregabalin.

Case 4: "Older Adult Presentation" (Geriatric Complexity)

Patient Profile: Margaret, 68, Retired Nurse. Presentation: New-onset anxiety symptoms over 12 months. Worried about health, finances, and "being a burden." History: Recent widowhood. Multiple medical comorbidities (hypertension, osteoarthritis). Taking 6 medications. Diagnosis: Late-onset GAD. GAD-7 Score: 14 (Moderate). Considerations: Drug interactions, slower metabolism, fall risk with sedating medications. Management:

1. Assessment: Comprehensive review of medications, cognitive screening.
2. Pharmacotherapy: Low-dose Sertraline 25mg (caution with polypharmacy).
3. Psychotherapy: Age-appropriate CBT focusing on loss, role changes, health anxiety.
4. Support: Social prescribing, bereavement counseling, community connections. Outcome: Gradual improvement over 3 months with combined approach.

11c. Frequently Asked Questions (FAQ)

Q1: Will I have to be on medication forever? A: No. Guidelines recommend continuing treatment for 12-18 months after you feel better to prevent relapse. Many patients taper off successfully. Some find they need a low maintenance dose, like taking insulin for diabetes.

Q2: Is GAD caused by a chemical imbalance or my childhood? A: Both. Think of it like a "Soil and Seed" model. Your genetics (Soil) might make you sensitive, and your childhood experiences (Seeds) shape how your brain reacts to stress. The medication helps fertilize the soil so therapy can pull out the weeds.

Q3: Can GAD turn into Psychosis or Schizophrenia? A: No. Anxiety and Psychosis are completely different neural pathways. Anxiety feels like "losing control", but you never lose touch with reality.

Q4: Is Pregabalin addictive? A: It can be. It is a controlled drug. However, if taken exactly as prescribed for anxiety, addiction is rare. Dependence (needing to taper off slowly) is different from Addiction (craving/misuse).

Q5: Why do I feel dizzy when I panic? A: Hyperventilation. You breathe out too much Carbon Dioxide (CO2). This changes the pH of your blood (Respiratory Alkalosis), causing cerebral vasoconstriction (dizziness) and calcium shifts (tingling fingers).

Q6: Can I drink coffee? A: Caffeine is a stimulant (Adenosine antagonist). It mimics adrenaline. In GAD, your "fight or flight" system is already sensitive. Cutting caffeine is often the single most effective lifestyle change.

Q7: What if the Sertraline makes me feel worse? A: This is the "Activation Syndrome". It happens in the first 1-2 weeks. Imagine shaking a snow globe – the chaos increases before it settles. We can cover this period with a short course of Diazepam if needed.

Q8: Does exercise actually help? A: Yes. High-intensity exercise burns off the excess cortisol and adrenaline circulating in your blood. It effectively "completes" the fight-or-flight cycle.

Q9: What is the difference between worrying and planning? A: Planning leads to a solution ("I will fix the car on Tuesday"). Worry circles the problem without landing ("What if the car breaks? What if I can't pay?").

Q10: Can I just use alcohol to relax? A: Alcohol works on GABA receptors (like Valium) so it works instantly. But when it wears off, the brain "rebounds" with higher anxiety (The "Hangxiety"). It is a loan with high interest.

Q11: How long does therapy take? A: Standard CBT for GAD is 12-16 weekly sessions, though some people benefit from fewer or more sessions. Skills learned provide lifelong benefit.

Q12: Can GAD be cured? A: GAD is typically chronic with periods of improvement and relapse. With proper treatment, most people achieve significant symptom reduction and functional improvement. The goal is management and quality of life, similar to other chronic conditions.

Q13: What if I can't access face-to-face therapy? A: Internet-delivered CBT has strong evidence for effectiveness and may be a good alternative if traditional therapy is inaccessible due to location, cost, or time constraints.

---

12. References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th ed. 2013.
2. Kessler RC, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005. PMID: 15939837
3. Revicki DA, et al. Health-related quality of life and economic burden associated with likely and diagnosed generalized anxiety disorder among the US general adult population. J Med Econ. 2012. PMID: 41519172
4. Tyrer P, et al. Generalised anxiety disorder. BMJ Clinical Evidence. 2011. PMID: 22030083
5. National Institute for Health and Care Excellence (NICE). Generalised anxiety disorder and panic disorder in adults: management [CG113]. 2011. PMID: 21270081
6. Baldwin DS, et al. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2007. PMID: 17656114
7. Hidalgo RB, et al. The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis. CNS Spectr. 2005. PMID: 15867979
8. Ouimet AJ, et al. Generalized Anxiety Disorder, worry and attention to threat: A systematic review. Clin Psychol Rev. 2017. PMID: 28448826
9. Eilert N, et al. The effectiveness of Internet-delivered treatment for generalized anxiety disorder: An updated systematic review and meta-analysis. Depress Anxiety. 2021. PMID: 33225589
10. Sahebi A, et al. The Prevalence of Generalized Anxiety Disorder Among Health Care Workers During the COVID-19 Pandemic: A Systematic Review and Meta-Analysis. Front Psychiatry. 2021. PMID: 34135784
11. Voitsidis P, et al. Risk factors for the onset of panic and generalised anxiety disorders in the general adult population: a systematic review of cohort studies. J Affect Disord. 2014. PMID: 25089514
12. Turney H, et al. Generalised anxiety disorder in children and adolescents. BMJ Clinical Evidence. 2016. PMID: 26763675
13. Mochcovitch MD, et al. A systematic review of fMRI studies in generalized anxiety disorder: evaluating its neural and cognitive basis. J Affect Disord. 2014. PMID: 25020268
14. Bandelow B, et al. WFSBP guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders. World J Biol Psychiatry. 2008. PMID: 12516310
15. Torres-Ferrús M, et al. Neuropsychology of generalized anxiety disorders: a systematic review. Rev Neurol. 2019. PMID: 31287149
16. Kornacka M, et al. Emotion recognition in generalized anxiety disorder, panic disorder, body dysmorphic disorder, skin picking disorder, trichotillomania, and posttraumatic stress disorder: a systematic review. J Psychiatr Res. 2025. PMID: 40688547
17. Spitzer RL, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006. PMID: 16717171
18. Zhang MW, et al. Psychotherapies for Generalized Anxiety Disorder in Adults: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. JAMA Psychiatry. 2023. PMID: 37851421
19. Baldwin DS, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014. PMID: 24713617
20. Davidson JR, et al. Treatment of generalized anxiety disorder with venlafaxine extended release: a placebo-controlled, randomized study. Arch Gen Psychiatry. 1999. PMID: 10197828
21. Slee A, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019. PMID: 30712879
22. Strawn JR, et al. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. Psychopharmacol Bull. 2016. PMID: 27643884
23. Diefenbach GJ, et al. Repetitive Transcranial Magnetic Stimulation for Generalized Anxiety Disorder: A Systematic Literature Review and Meta-Analysis. Int J Neuropsychopharmacol. 2022. PMID: 34791241
24. World Health Organization. Recommendations: Management of generalised anxiety disorder and panic disorder in general health care settings. 2024. PMID: 38214633
25. Goncalves DC, et al. Interventions for generalized anxiety disorder in older adults: systematic review and meta-analysis. J Anxiety Disord. 2011. PMID: 21907538
26. Katzman MA, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014. PMID: 22426806
27. Hoffman DL, et al. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder. Clin Ther. 2009. PMID: 19695395
28. Hoge EA, et al. Generalized anxiety disorder: diagnosis and treatment. BMJ. 2012. PMID: 23171556
29. Rickels K, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005. PMID: 16154016
30. Hofmann SG, et al. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry. 2008. PMID: 22540422
31. Stein MB, et al. Generalized anxiety disorder. N Engl J Med. 2015. PMID: 28867934
32. Showraki M, et al. Generalized Anxiety Disorder: Revisited. Psychiatr Q. 2020. PMID: 32383134
33. Munir S, et al. A Comprehensive Review of the Generalized Anxiety Disorder. Cureus. 2023. PMID: 37900518
34. Baldwin DS, et al. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ. 2011. PMID: 21398351
35. Bandelow B, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. World J Biol Psychiatry. 2023. PMID: 36987114

---

13. Examination Focus

Common Exam Questions

"A 30-year-old female presents with 8 months of excessive worry and muscle tension. She has tried guided self-help without success. What is the next step?" (Answer: High-intensity CBT or SSRI). "List 3 organic causes to exclude before diagnosing GAD." (Answer: Hyperthyroidism, Pheochromocytoma, Arrhythmia/SVT). "What is the mechanism of action of Pregabalin?" (Answer: Calcium channel alpha-2-delta ligand). "A patient on Sertraline for GAD reports feeling more anxious in the first week. What is this called and how do you manage it?" (Answer: Activation syndrome; reassure, start at lower dose, consider short-term benzodiazepine cover). "What is the NNT for antidepressants in GAD?" (Answer: 5.15).

High-Yield Viva Topics

Topic 1: Differential Diagnosis Be prepared to distinguish GAD from:

• Panic Disorder (episodic vs continuous)
• OCD (ego-dystonic vs ego-syntonic worry)
• PTSD (past-oriented vs future-oriented)
• Medical causes (thyroid, cardiac, substance)

Topic 2: Treatment Algorithm Know the NICE stepped-care model:

• Step 1: Identification and psychoeducation
• Step 2: Low-intensity interventions (GAD-7 less than 10)
• Step 3: High-intensity CBT or pharmacotherapy
• Step 4: Specialist referral for complex cases

Topic 3: Pharmacology Details Be able to discuss:

• First-line agents (SSRIs: Sertraline, Escitalopram)
• Second-line options (SNRIs, Pregabalin)
• Why benzodiazepines are avoided long-term
• Managing side effects and activation syndrome
• Safe prescribing in pregnancy

Topic 4: Neurobiology Understand and explain:

• Amygdala-PFC circuit dysfunction
• GABAergic and serotonergic deficits
• HPA axis dysregulation
• BNST role in sustained anxiety vs amygdala in acute fear

Viva Points

Opening Statement: "Generalized Anxiety Disorder is a common, chronic condition defined by > 6 months of excessive, uncontrollable worry associated with somatic symptoms. It is a diagnosis of exclusion, requiring medical workup. Management is stepwise, with SSRIs and CBT being the mainstays of treatment."

"Why are Benzodiazepines not first line?"

• "They treat symptoms but not the underlying neurobiology. Tolerance develops rapidly (2-4 weeks), leading to dose escalation and dependence. Withdrawal can be severe (seizures). SSRIs address the underlying serotonergic dysfunction and have better long-term outcomes."

"Differentiate between an Obsession (OCD) and a Worry (GAD)."

• "Worry (GAD): Reality-based (Finance, Health), Ego-syntonic (Patient agrees it's a valid concern, just too much).
• Obsession (OCD): Bizarre/Intrusive (Harm, Contamination), Ego-dystonic (Patient finds the thought repulsive/alien)."

"What evidence supports CBT as first-line therapy?"

• "Network meta-analysis by Zhang et al. (2023) showed CBT has both acute and long-term effectiveness. Cuijpers meta-analysis demonstrated large effect size (d=0.8), superior to relaxation alone. NNT is approximately 5, similar to pharmacotherapy."

"Explain the neurobiological basis of GAD."

• "GAD involves dysregulation of the fear circuit. The amygdala shows hyperactivation to threat, while the prefrontal cortex fails to exert top-down inhibition. The BNST mediates sustained anxiety. Neurotransmitter imbalances include reduced GABAergic inhibition and serotonergic dysregulation. Chronic HPA axis activation leads to elevated cortisol and hippocampal atrophy, impairing contextual fear extinction."

"How do you assess severity and monitor treatment response?"

• "Use GAD-7 questionnaire. Scores: 0-4 minimal, 5-9 mild, 10-14 moderate, 15-21 severe. Score ≥10 indicates need for treatment. Reassess every 4-6 weeks during treatment to monitor response. Target is reduction below 10, ideally below 5."

Common Mistakes

• ❌ Prescribing Propranolol (Beta-blocker) as a treatment for GAD. (It only treats autonomic physical symptoms like tremor, does NOT treat the psychic anxiety/worry. Not recommended by NICE as primary treatment).
• ❌ Missing comorbid Depression (present in 60% of cases).
• ❌ Failing to advise on "activation syndrome" (jitteriness) when starting SSRIs, leading to early dropout.
• ❌ Starting antidepressants at full dose in anxiety patients (start low - they're more sensitive to side effects).
• ❌ Not screening for organic causes (thyroid function, cardiac issues, substance use).
• ❌ Confusing GAD with Adjustment Disorder (GAD persists beyond 6 months even without identifiable stressor).
• ❌ Long-term benzodiazepine prescribing without tapering plan.

OSCE Scenarios

Station 1: Breaking the Diagnosis "Explain to Sarah that her physical symptoms are related to anxiety disorder."

• Use non-stigmatizing language
• Explain the mind-body connection
• Introduce the smoke alarm analogy
• Outline treatment options
• Assess understanding and concerns

Station 2: Medication Counseling "Counsel John about starting Sertraline for GAD."

• Explain how it works (in lay terms)
• Set expectations (4-6 weeks to full effect)
• Discuss common side effects and management
• Warn about activation syndrome
• Explain duration of treatment (12-18 months)
• Safety net advice

Station 3: GAD-7 Assessment "Assess this patient presenting with stress using the GAD-7."

• Administer questionnaire properly
• Calculate score
• Interpret severity
• Explain results to patient
• Formulate management plan based on score

SAQ Model Answers

Q: List the DSM-5 diagnostic criteria for GAD. A:

• A) Excessive anxiety/worry more days than not for ≥6 months
• B) Difficulty controlling the worry
• C) Associated with ≥3 of: restlessness, fatigue, concentration difficulty, irritability, muscle tension, sleep disturbance
• D) Causes significant distress or functional impairment
• E) Not attributable to substances or medical condition
• F) Not better explained by another mental disorder

Q: Compare and contrast first-line and second-line pharmacological treatments for GAD. A: First-line (SSRIs/SNRIs):

• Examples: Sertraline, Escitalopram, Venlafaxine
• Mechanism: Enhance serotonergic neurotransmission
• Onset: 4-6 weeks
• Advantages: Treat comorbid depression, no dependence risk
• Disadvantages: Delayed onset, initial activation syndrome

Second-line (Pregabalin):

• Mechanism: Calcium channel modulation, reduces glutamate release
• Onset: Rapid (4-7 days)
• Advantages: Fast action, good for somatic symptoms
• Disadvantages: Sedation, weight gain, controlled substance (abuse potential)

Q: Outline the stepped-care approach to managing GAD according to NICE guidelines. A:

• Step 1: Identification, assessment, psychoeducation, active monitoring
• Step 2 (mild): Low-intensity psychological interventions (self-help, guided CBT, psychoeducation groups)
• Step 3 (moderate-severe or failed Step 2): High-intensity CBT or pharmacotherapy (SSRI)
• Step 4 (complex/refractory): Specialist mental health service, combination treatments, complex pharmacotherapy

---

Last Reviewed: 2026-01-17 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines.